T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing
Eoin Dinneen,Gregory L Shaw,Roseann Kealy,P. Alexandris,Kier Finnegan,Nadia Haidar,Sara Santos-Vidal,Sakunthala C. Kudahetti,Caroline M. Moore,Alistair Grey,Daniel M. Berney,Anju Sahdev,Paul Cathcart,R T D Oliver,Jack Cuzick,S. Madaan,Jhumur Pati,Abdul Matin Chowdhury,Brian Birch,Tim Dudderidge,K Jefferson,Howard Kynaston,Prabhakar Rajan,James Green,Thomas Powles,Victoria Kemp,Kim Chu +26 more
TL;DR: To test the feasibility of a randomised controlled trial (RCT) of aspirin and/or vitamin D3 in active surveillance (AS) low/favourable intermediate risk prostate cancer (PCa) patients with Prolaris® testing.
Journal ArticleDOI
Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151
Cristina Suarez,Toni K. Choueiri,David F. McDermott,Bernard Escudier,Michael B. Atkins,Thomas Powles,Brian I. Rini,Robert J. Motzer,Sumanta K. Pal,Lawrence Fong,U. De Giorgi,Yulei Wang,Tarik Khaznadar,F. Di Nucci,Constanze Kaiser,Darren Tayama,Frede Donskov +16 more
Journal ArticleDOI
What do Emergency Physicians Know About Immune Checkpoint Inhibitor-Related Toxicities: A Brief Report
Thomas Butters,Wing K Liu,M. Grant,Francesca Jackson-Spence,Ghufoor Zaynub,Alfred So,James Lam,Mehran Ashfar,Deborah Enting,Thomas Powles,Bernadett Szabados +10 more
TL;DR: Knowledge and management of immune mediated toxicities is inferior compared to chemotherapy across physicians working in major ED departments in London, highlighting the need for increased education on ICI amongst ED clinicians.
Journal ArticleDOI
The role of modern immunotherapy in metastatic urothelial cancer: mini review
Francesca Jackson-Spence,C. Toms,Yu-Hsuen Yang,Leo Jurascheck,Julia Choy,L Flanders,Bernadett Szabados,Thomas Powles +7 more
TL;DR: The maintenance approach, sequencing chemotherapy with ICIs, could be considered a best of both worlds approach, achieving initial control with chemotherapy, which is maintained in some individuals with avelumab, however, outcomes for patients with metastatic UC remain poor.